🧪
hypothesis

Endosomal-Retromer Trafficking Defect as a Shared Sorting Failure

Hypothesis

Endosomal-Retromer Trafficking Defect as a Shared Sorting Failure

Disrupted retrieval of cargo from endosomes to the trans-Golgi network (retromer dysfunction) impairs processing of APP, α-synuclein trafficking, and TDP-43 clearance.
🧬 VPS35, VPS26, SORL1, SNX27🩺 neurodegeneration🎯 Composite 64%💱 $0.56▼12.1%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 4 support 3 oppose
✓ All Quality Gates Passed
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite64%

🧪 Overview

Disrupted retrieval of cargo from endosomes to the trans-Golgi network (retromer dysfunction) impairs processing of APP, α-synuclein trafficking, and TDP-43 clearance. SORL1 variants increase AD risk; VPS35 D620N causes familial PD. The mechanism represents one of the cleaner intersections between AD and PD. However, less convincing for ALS/FTD and no mature clinical precedent exists. Best development path is genetically enriched AD/PD subsets rather than pan-NDD indication.

🧬 Mechanism

🔗 Mechanism from KG for VPS35, VPS26, SORL1, SNX27

Auto-built from this analysis's top knowledge-graph edges.

graph TD
    GBA1_mutations["GBA1 mutations"] -->|increases risk| PD["PD"]
    TREM2_R47H_variant["TREM2 R47H variant"] -->|increases risk| Ad["Ad"]
    alpha_synuclein_fibrils["alpha-synuclein fibrils"] -->|activates| NLRP3_Inflammasome["NLRP3 Inflammasome"]
    TFEB_overexpression["TFEB overexpression"] -.->|inhibits| tau_A__pathology["tau/Aβ pathology"]
    TARDBP_MUTATIONS["TARDBP MUTATIONS"] -->|causes| ALS_FTD["ALS/FTD"]
    TDP_43_INCLUSIONS["TDP-43 INCLUSIONS"] -->|associated with| ALS_FTD_1["ALS/FTD"]
    NfL_reduction["NfL reduction"] -->|biomarker for| als["als"]
    TARDBP["TARDBP"] -->|cross disease mech| ALS["ALS"]
    TARDBP_2["TARDBP"] -->|cross disease mech| FTD["FTD"]
    TARDBP_3["TARDBP"] -->|cross disease mech| AD_LATE["AD/LATE"]
    h_cross_synth_tdp43_rna_p["h-cross-synth-tdp43-rna-proteostasis"] -->|proposes shared me| TARDBP_4["TARDBP"]
    SNCA["SNCA"] -->|cross disease mech| PD_5["PD"]
    style GBA1_mutations fill:#ce93d8,stroke:#333,color:#000
    style PD fill:#ef5350,stroke:#333,color:#000
    style TREM2_R47H_variant fill:#ce93d8,stroke:#333,color:#000
    style Ad fill:#ef5350,stroke:#333,color:#000
    style alpha_synuclein_fibrils fill:#4fc3f7,stroke:#333,color:#000
    style NLRP3_Inflammasome fill:#ce93d8,stroke:#333,color:#000
    style TFEB_overexpression fill:#4fc3f7,stroke:#333,color:#000
    style tau_A__pathology fill:#4fc3f7,stroke:#333,color:#000
    style TARDBP_MUTATIONS fill:#ce93d8,stroke:#333,color:#000
    style ALS_FTD fill:#ef5350,stroke:#333,color:#000
    style TDP_43_INCLUSIONS fill:#4fc3f7,stroke:#333,color:#000
    style ALS_FTD_1 fill:#ef5350,stroke:#333,color:#000
    style NfL_reduction fill:#ce93d8,stroke:#333,color:#000
    style als fill:#ef5350,stroke:#333,color:#000
    style TARDBP fill:#4fc3f7,stroke:#333,color:#000
    style ALS fill:#ef5350,stroke:#333,color:#000
    style TARDBP_2 fill:#4fc3f7,stroke:#333,color:#000
    style FTD fill:#ef5350,stroke:#333,color:#000
    style TARDBP_3 fill:#4fc3f7,stroke:#333,color:#000
    style AD_LATE fill:#ef5350,stroke:#333,color:#000
    style h_cross_synth_tdp43_rna_p fill:#4fc3f7,stroke:#333,color:#000
    style TARDBP_4 fill:#4fc3f7,stroke:#333,color:#000
    style SNCA fill:#4fc3f7,stroke:#333,color:#000
    style PD_5 fill:#ef5350,stroke:#333,color:#000

⚖️ Evidence

⚖️ Evidence Matrix4 supports3 contradicts
Supports
SORL1 variants increase AD risk with functional impact on APP trafficking
PMID:19103625
Supports
VPS35 D620N mutation causes late-onset familial PD with retromer impairment
PMID:23077058
Supports
Retromer protein levels reduced in AD brain; VPS35 overexpression reduces Aβ in mice
PMID:21908926
Supports
Genetic variants in retromer components identified across NDD GWAS
PMID:28714951
Contradicts
No mature clinical precedent for retromer-targeted drugs
PMID:Preclinical stage only
Contradicts
Less convincing evidence for ALS/FTD relevance
PMID:ALS spinal cord studies
Contradicts
VPS35 gene therapy or overexpression is too early and safety-sensitive
PMID:Development stage assessment
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — VPS35

No curated PDB or AlphaFold mapping for VPS35 yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for VPS35, VPS26, SORL1, SNX27 →

No DepMap CRISPR Chronos data found for VPS35, VPS26, SORL1, SNX27.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.8%
Volatility
Low
0.0019
Events (7d)
3
Price History
▼12.1%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF skin fibroblasts from VPS35 D620N mutation carriers (familial PD) are stratified against age-matched sporadic PD and healthy controls, THEN VPS35 protein expression will be reduced by ≥40% and endo≥40% reduction in VPS35 protein by quantitative western blot; ≥50% delayed clearance of transferrin receptor (endosomal recycling marker) by live-cell imaging.— no observation —pending0.58
IF human iPSC-derived neurons harboring SORL1 missense risk variants are treated with a VPS26/VPS35 retromer-complex stabilizer (e.g., pharmacological chaperone at 10μM for 14 days), THEN secreted Aβ4≥30% reduction in Aβ42/Aβ40 ratio in conditioned media, measured by multiplexed immunoassay (Electrochemiluminescence).— no observation —pending0.62
🔮 Falsifiable Predictions (2)
pendingconf 62%
IF human iPSC-derived neurons harboring SORL1 missense risk variants are treated with a VPS26/VPS35 retromer-complex stabilizer (e.g., pharmacological chaperone at 10μM for 14 days), THEN secreted Aβ42/Aβ40 ratio will decrease by ≥30% compared to vehicle-treated isogenic controls within 4 weeks.
Predicted outcome: ≥30% reduction in Aβ42/Aβ40 ratio in conditioned media, measured by multiplexed immunoassay (Electrochemiluminescence).
Falsification: No statistically significant change in Aβ42/Aβ40 ratio (p>0.05, two-tailed t-test) between retromer-stabilizer and vehicle conditions in SORL1 variant neurons.
pendingconf 58%
IF skin fibroblasts from VPS35 D620N mutation carriers (familial PD) are stratified against age-matched sporadic PD and healthy controls, THEN VPS35 protein expression will be reduced by ≥40% and endosomal cargo周转率 will be impaired by ≥50% within 3 months.
Predicted outcome: ≥40% reduction in VPS35 protein by quantitative western blot; ≥50% delayed clearance of transferrin receptor (endosomal recycling marker) by live-cell
Falsification: VPS35 protein levels and endosomal trafficking kinetics are statistically indistinguishable between VPS35 D620N carriers and sporadic PD/controls (p>0.05 by ANOVA with Bonferroni correction).
View on SciDEX ↗